This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Telcyta

MabVax Therapeutics Holdings, Inc.

Drug Names(s): TLK286, TER286, canfosfamide HCL

Description: Telcyta, a glutathione analog, is activated by an enzyme – glutathione S-transferase – that is enriched in cancer cells. Once activated, the drug causes apoptosis (programmed cell death), leading to the killing of cancer cells. Direct triggering of apoptosis in cancer cells is a promising approach, enhancing natural processes that lead to tumor cell death.

Deal Structure: Telik and MabVax
In May 2014, Telik and MabVax have entered into a definitive merger agreement. Under the terms of the merger agreement, MabVax will merge with a wholly-owned subsidiary of Telik in an all-stock transaction.


Telcyta News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug